Fascinating, thanks for the links. These findings might be preliminary, as this criticism of the claims lays out the case that it might be premature to make such assertions this early.
The commercialization of the MEND protocol might have run into some partnership issues between the original researcher and the first company he worked with dispensing the treatment: